Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaret Sutherland

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Neurology|August 1, 2014
Recommendations of the Alzheimer's disease-related dementias conferenceThomas J Montine, Walter J Koroshetz, Debra Babcock, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 10, 2012
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug developmentAdam L Boxer, Michael Gold, Edward Huey, et al.
Biomarkers in Medicine|June 24, 2017
Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers ProgramKatrina Gwinn, Karen K David, Christine Swanson-Fischer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 1, 2019
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measuresAdam L Boxer, Michael Gold, Howard Feldman, et al.
Neurobiology of Aging|December 3, 2014
NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseasesMike A Nalls, Jose Bras, Dena G Hernandez, et al.
Science Translational Medicine|August 17, 2018
Finding useful biomarkers for Parkinson's diseaseAlice S Chen-Plotkin, Roger Albin, Roy Alcalay, et al.
The Lancet. Neurology|August 15, 2015
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling studyMike A Nalls, Cory Y McLean, Jacqueline Rick, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 16, 2012
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)Adam L Boxer, Michael Gold, Edward Huey, et al.
Nature Genetics|July 28, 2014
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's diseaseMike A Nalls, Nathan Pankratz, Christina M Lill, et al.
Plos One|September 7, 2012
Creation of an open-access, mutation-defined fibroblast resource for neurological disease researchSelina Wray, Matthew Self, , et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Neurology|August 1, 2014
Recommendations of the Alzheimer's disease-related dementias conferenceThomas J Montine, Walter J Koroshetz, Debra Babcock, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 10, 2012
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug developmentAdam L Boxer, Michael Gold, Edward Huey, et al.
Biomarkers in Medicine|June 24, 2017
Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers ProgramKatrina Gwinn, Karen K David, Christine Swanson-Fischer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 1, 2019
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measuresAdam L Boxer, Michael Gold, Howard Feldman, et al.
Neurobiology of Aging|December 3, 2014
NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseasesMike A Nalls, Jose Bras, Dena G Hernandez, et al.
Science Translational Medicine|August 17, 2018
Finding useful biomarkers for Parkinson's diseaseAlice S Chen-Plotkin, Roger Albin, Roy Alcalay, et al.
The Lancet. Neurology|August 15, 2015
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling studyMike A Nalls, Cory Y McLean, Jacqueline Rick, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 16, 2012
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)Adam L Boxer, Michael Gold, Edward Huey, et al.
Nature Genetics|July 28, 2014
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's diseaseMike A Nalls, Nathan Pankratz, Christina M Lill, et al.
Plos One|September 7, 2012
Creation of an open-access, mutation-defined fibroblast resource for neurological disease researchSelina Wray, Matthew Self, , et al.
Pageof 4